Abstract
We have assessed the propensity of β-adrenoceptor blockers to cause muscle cramps and to raise the serum creatine phosphokinase (CPK) level in 78 patients with essential hypertension. After a control period, a β-adrenoceptor blocker without intrinsic sympathomimetic activity (ISA; propranolol, metoprolol or arotinolol) was administered for three months. Thereafter, the patients were randomised to receive a β-adrenoceptor blocker with ISA (pindolol or carteolol) for three months or a β-adrenoceptor blocker without ISA for a further three months. This pattern was continued until all β-adrenoceptor blockers had been given. At the end of each period, CPK and CPK-MB levels were measured.
Of the 78 subjects, muscle cramps occurred in 27 during treatment with pindolol and 32 during treatment with carteolol. No complaints were made by subjects treated with propranolol and arotinolol, but muscle cramps were reported in 2 treated with metoprolol. While muscle cramps were caused both by pindolol and carteolol in 16 subjects, they were caused by either of these drugs in the remainder of the subjects. Muscle cramp occurred mainly in the calves when the patients were in bed at night. Serum CPK and CPK-MB levels increased significantly during treatment with pindolol (control period vs pindolol, CPK=96 vs 133 IU · ml−1, CPK-MB=14 vs 18 IU · ml−1) or carteolol (CPK=117 IU · ml−1, CPK-MB=18 IU · ml−1) while the levels during treatment with propranolol, arotinolol and metoprolol did not change from those in the control period. The change in serum CPK during treatment with carteolol or pindolol was significantly correlated with the control serum CPK level. No correlation was observed between muscle cramps and serum CPK level. There were individual differences in the severity of muscle cramps, with some subjects complaining frequently of severe muscle cramps.
Because muscle cramps are frequently experienced at night, they disturb sleep and lower the quality of life in patients. This problem should be considered during treatment with β-adrenoceptor blockers with ISA.
Similar content being viewed by others
References
Herishanu Y, Rosenberg P (1975) β-blockers and myasthenia gravis. Ann Intern Med 83: 834–835
Hughes RO, Zacharias FJ (1976) Myasthenic syndrome during treatment with practolol. Br Med J 1: 460–461
Forfar JC, Brown GJ, Cull RE (1979) Proximal myopathy during beta-blockade. Br Med J 2: 1331–1332
Shaivitz SA (1979) Timolol and myasthenia gravis. JAMA 242: 1611–1612
Teicher A, Rosenthal T, Kissin E, Sarova I (1981) Labetalol-induced toxic myopathy. Br Med J 282: 1824–1825
Imataka K, Seki A, Takahashi N, Fujii J, Ohuchi Y, Kuwako K, Umeda T, Machii K, Hasegawa T, Ozoe A (1981) Elevation of serum creatine phophokinase during pindolol treatment (in Japanese). Jpn J Med 70: 580–585
Anthony M, Lance JW, Somerville B (1972) A comparative trial of prindolol, clonidine and carbamazepine in the interval therapy of migraine. Med J Aust 1: 1343–1346
Gonasun LM, Langrall H (1982) Adverse reactions to pindolol administration. Am Heart J 104: 482–486
Greminger P, Vetter H, Boerlin HJ, Havelka J, Baumgart P, Walger P, Lüscher T, Siegenthaler W, Vette W (1983) A comparative study between 100 mg atenolol and 20 mg pindolol slow-release in essential hypertension. Drugs 25 [Suppl 2]: 37–41
Saruta T, Itoh H (1983) Changes of CPK and CPK isozymes on the administration of several β-adrenoceptor blockers (in Japanese). Pharmacol Treat 7: 145–154
Morgan TO, Anevekar SN, Sahto J, Louis WJ, Doyle AE (1974) A comparison of beta-adrenergic blocking drugs in the treatment of hypertension. Postgrad Med J 50: 253–259
Prichard BNC (1978) β-Adrenergic receptor blockade in hypertension, past, present and future. J Clin Pharmacol 379–399
Rosalki SB (1967) An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med 69: 696–705
Empfehlungen der Deutschen Gesellschaft für Klinische Chemie (1977) Standard-Methode zur Bestimmung der Aktivität der Kreatin-Kinase. J Clin Chem Clin Biochem 15: 249–254
Wüerzburg U, Hennrich N, Orth HD, Lang H (1977) Quantitative determination of creatine kinase isoenzyme catalytic concentrations in serum using immunological methods. J Clin Chem Clin Biochem 15: 131–137
Larochelle P, Hamet P, Hoffman B, Kuchel O, Mckenzie J, Mitenko P, Ogilvie RI, Rudy J (1980) Labetalol in essential hypertension. J Cardiovasc Pharmacol 2: 751–759
Thomson WHS (1986) Determination and statistical analyses of the normal ranges for five serum enzymes. Clin Chim Acta 21: 469–478
Griffiths PD (1966) Serum levels of ATP: creatine phosphotranspherase (creatine kinase). The normal range and effect of muscular activity. Clin Chim Acta 13: 413–420
Paterson Y, Lawrence EF (1972) Factors affecting serum creatine phosphokinase levels in normal adult females. Clin Chim Acta 42: 131–139
Marsden CD, Foley TH, Owen DAL, McAllister RG (1967) Peripheral β-adrenergic receptors concerned with tremor. Clin Sci 33: 53–65
Marlin GE, Turner P (1975) Comparison of the β2-adrenoceptor selectivity of rimitelol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol 2: 41–48
Larsson S, Svedmyr N (1977) Tremor caused by sympathomimetics is mediated by beta2-adrenoceptors. Scand J Resp Dis 58: 5–10
Sato S, Ikeda H, Yasui S, Takahashi K (1987) Cramp of voluntary muscles in patients with bronchial asthma treated with beta-receptor stimulants (in Japanese). Kokyu 6: 334–337
Bowman WC, Zaimis E (1958) The effects of adrenaline, noradrenaline and isoprenaline on skeletal muscle contractions in the cat. J Physiol 144: 92–107
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Imai, Y., Watanabe, N., Hashimoto, J. et al. Muscle cramps and elevated serum creatine phosphokinase levels induced by β-adrenoceptor blockers. Eur J Clin Pharmacol 48, 29–34 (1995). https://doi.org/10.1007/BF00202168
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00202168